NuVasive to Pay $13.5 Million to Settle False Claims Charge

California-based medical device manufacturer NuVasive will pay $13.5 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal healthcare programs for spine surgeries by marketing the company’s CoRoent System for surgical uses that were not approved by the U.S. Food and Drug Administration (FDA).

nuvasive

The settlement also resolves allegations that NuVasive caused false claims by paying kickbacks to induce physicians to use the company’s CoRoent System.

The civil settlement resolves a lawsuit filed under the whistleblower provision of the False Claims Act by Kevin Ryan, a former NuVasive sales representative.

Ryan will receive approximately $2.2 million.

Federal officials alleged that between 2008 and 2013, NuVasive promoted the use of the CoRoent System for surgical uses that were not approved or cleared by the FDA, including for use in treating two complex spine deformities, severe scoliosis and severe spondylolisthesis.

As a result of this conduct, the United States alleged that NuVasive caused physicians and hospitals to submit false claims to federal healthcare programs for certain spine surgeries that were not eligible for reimbursement.

The settlement agreement also resolves allegations that NuVasive knowingly offered and paid illegal remuneration to certain physicians to induce them to use the CoRoent System in spine fusion surgeries, in violation of the federal Anti-Kickback Statute.

The illegal remuneration consisted of promotional speaker fees, honoraria and expenses relating to physicians’ attendance at events sponsored by a group known as the Society of Lateral Access Surgery (SOLAS).

SOLAS was allegedly created, funded and operated solely by NuVasive, despite its outward appearance of independence.

Copyright © Corporate Crime Reporter
In Print 48 Weeks A Year

Built on Notes Blog Core
Powered by WordPress